Researchers are now digging deep into ways to keep the metabolic benefits while reducing or eliminating those side effects
FDAs 2025 Increase in Warning Letters on Compounded Drug Advertising In recent remarks at the Food and Drug Law Institutes Enforcement, Litigation, and Compliance Conference, the director of the Office of Compliance within FDAs Center for Drug Evaluation and Research's (CDER) noted that 22% of warning letters that CDER issued in fiscal year (FY) 2025 were sent to telehealth platforms and other entities related to claims made regarding compounded drug products, including compounded GLP-1s
Why isn't this another example of a 503B effectively also operating as a 503A compounding (non carbon copies) of tirzepatide with B6 to try and continue getting a piece of the "personalized" GLP-1 pie
Intermediate doses of 7.5 mg and 12.5 mg are available as titration steps if needed
NICE guidance on obesity management (CG189 and recent technology appraisals) recommends a stepwise approach: First-line: Lifestyle interventions including dietary modification, increased physical activity, and behavioural support Pharmacotherapy: Consider when BMI 35 kg/m (or 30 kg/m with comorbidities) and lifestyle measures have been insufficient Licensed options: Orlistat remains a primary pharmacological option in NHS formularies, with GLP-1 receptor agonists like semaglutide (Wegovy) now available through specialist services for those with BMI 35 kg/m (or 30 kg/m with comorbidities) and at least one weight-related comorbidity Bariatric surgery: Considered for those with BMI 40 kg/m (or 35 kg/m with comorbidities) when other measures have failed NICE guidance emphasises using licensed medications with established safety profiles and does not recommend combining weight loss drugs without robust evidence
)
)
